Omeros (NASDAQ:OMER) Upgraded at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Omeros (NASDAQ:OMER) from a strong sell rating to a sell rating in a research note published on Friday, BidAskClub reports.

Several other research analysts also recently commented on the company. Zacks Investment Research cut shares of Omeros from a hold rating to a sell rating in a report on Saturday, November 16th. Maxim Group reissued a buy rating and issued a $25.00 price objective on shares of Omeros in a research note on Thursday, December 5th. HC Wainwright restated a buy rating and issued a $34.00 target price (down previously from $35.00) on shares of Omeros in a research report on Monday, December 2nd. ValuEngine lowered shares of Omeros from a hold rating to a sell rating in a research report on Thursday, November 14th. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Omeros in a research note on Wednesday, December 4th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $24.00.

NASDAQ:OMER opened at $13.64 on Friday. Omeros has a 12-month low of $12.52 and a 12-month high of $20.92. The stock’s 50 day moving average price is $13.97 and its two-hundred day moving average price is $15.71. The firm has a market capitalization of $678.31 million, a price-to-earnings ratio of -8.52 and a beta of 2.63.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.08. The company had revenue of $29.86 million during the quarter, compared to the consensus estimate of $27.19 million. Omeros’s revenue for the quarter was up 547.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.81) earnings per share. On average, equities research analysts forecast that Omeros will post -1.07 earnings per share for the current fiscal year.

In other news, Director Thomas J. Cable sold 10,000 shares of Omeros stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $13.16, for a total transaction of $131,600.00. Company insiders own 12.80% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in OMER. Charles Schwab Investment Management Inc. lifted its stake in Omeros by 1.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 268,719 shares of the biopharmaceutical company’s stock valued at $4,217,000 after buying an additional 3,725 shares during the period. Northern Trust Corp raised its holdings in shares of Omeros by 0.9% during the second quarter. Northern Trust Corp now owns 636,210 shares of the biopharmaceutical company’s stock valued at $9,982,000 after purchasing an additional 5,642 shares during the period. Parametric Portfolio Associates LLC raised its holdings in shares of Omeros by 13.9% during the second quarter. Parametric Portfolio Associates LLC now owns 39,578 shares of the biopharmaceutical company’s stock valued at $621,000 after purchasing an additional 4,842 shares during the period. United Capital Financial Advisers LLC raised its holdings in shares of Omeros by 2.5% during the second quarter. United Capital Financial Advisers LLC now owns 100,743 shares of the biopharmaceutical company’s stock valued at $1,581,000 after purchasing an additional 2,475 shares during the period. Finally, BlackRock Inc. boosted its position in shares of Omeros by 1.1% during the 2nd quarter. BlackRock Inc. now owns 3,858,463 shares of the biopharmaceutical company’s stock worth $60,539,000 after purchasing an additional 40,412 shares in the last quarter. 51.42% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Article: What does the Dogs of the Dow mean?

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GAM Holding AG Decreases Holdings in Lear Co.
GAM Holding AG Decreases Holdings in Lear Co.
GAM Holding AG Makes New Investment in FirstEnergy Corp.
GAM Holding AG Makes New Investment in FirstEnergy Corp.
GAM Holding AG Sells 1,916 Shares of Constellation Brands, Inc.
GAM Holding AG Sells 1,916 Shares of Constellation Brands, Inc.
GAM Holding AG Reduces Stock Position in Philip Morris International Inc.
GAM Holding AG Reduces Stock Position in Philip Morris International Inc.
GAM Holding AG Makes New $332,000 Investment in Nordson Co.
GAM Holding AG Makes New $332,000 Investment in Nordson Co.
Cracker Barrel Old Country Store, Inc.  Shares Sold by GAM Holding AG
Cracker Barrel Old Country Store, Inc. Shares Sold by GAM Holding AG


 
© 2006-2020 Zolmax.